By Scott Gottlieb (original source Health Affairs)
“In recent years, considerable bipartisan Congressional action, leadership from both Democratic and Republican administrations, and broad-based multistakeholder collaborations have focused on improving the tools and regulatory processes at the Food and Drug Administration (FDA), other government agencies, and public-private collaborations to support more efficient and timely development of new medical technologies. Enhanced funding through user fees and the bipartisan Twenty-First Century Cures legislation have supported a robust and better-resourced FDA and enabled science-driven collaborations in a range of areas including innovative clinical trials, “patient-focused” drug development, and greater clarity around standards for regulatory approval of new technologies.”
Click here to read more
Leana Wen: How long does covid booster protection last?
More evidence highlighting the benefit, and limitations, of covid-19 vaccines. After the Centers for Disease Control and Prevention shifted its coronavirus vaccine guidance from a…
Thought Leader: Leana Wen
Dr. Sanjay Gupta: How Wearable Tech Transforms Health
We’ve come a long way in integrating technology into our daily lives, but could wearable tech actually help you live longer? From detecting heartbeat irregularities to flagging signs of…
Thought Leader: Sanjay Gupta
Annie Leibovitz Celebrated Women Alongside Her Many Muses
Annie Leibovitz has captured some of fashion’s most indelible images over the past five decades—oftentimes for this magazine. Many of those photographs—from Queen Elizabeth II…
Thought Leader: Annie Leibovitz
Scott Gottlieb on China’s biotech strategy
Thought Leader: Scott Gottlieb
Scott Gottlieb: China’s edge over U.S. biotech
Thought Leader: Scott Gottlieb
